Founded in April 2024 by sisters Olivia and Chloe Ferro, SheMed develops personalized weight-loss and wellness programs for women that pair GLP-1 drugs such as Wegovy and Mounjaro with laboratory blood tests and ongoing care. The platform has attracted more than 60,000 subscribers in under a year, reflecting strong demand for prescription weight-management solutions in the UK. Unlike rivals that rely on self-reported BMI, SheMed’s clinical model uses blood analyses to determine eligibility and tailor treatment, aiming to improve both metabolic and hormonal health outcomes. Most recent users have selected Novo Nordisk’s Wegovy following price increases for Eli Lilly’s Mounjaro. The company earns subscription revenue from these programs, though specific financial figures were not disclosed. With new capital, SheMed plans to expand nationwide, fund additional research initiatives, and improve access to personalized female-focused care. It also expects to publish a study this month using participant data to examine how GLP-1 drugs affect hormonal and metabolic health beyond weight loss.

Total raised

$50M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2025